4 research outputs found

    A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort

    Get PDF
    Hormone-receptor positive; Chemotherapy; Early-stage breast cancerReceptor de hormonas positivo; Quimioterapia; Cáncer de mama en fase inicialReceptor d'hormones positiu; Quimioteràpia; Càncer de mama en fase inicialCanAssist Breast (CAB), a prognostic test uses immunohistochemistry (IHC) approach coupled with artificial intelligence-based machine learning algorithm for prognosis of early-stage hormone-receptor positive, HER2/neu negative breast cancer patients. It was developed and validated in an Indian cohort. Here we report the first blinded validation of CAB in a multi-country European patient cohort. FFPE tumor samples from 864 patients were obtained from-Spain, Italy, Austria, and Germany. IHC was performed on these samples, followed by recurrence risk score prediction. The outcomes were obtained from medical records. The performance of CAB was analyzed by hazard ratios (HR) and Kaplan Meier curves. CAB stratified European cohort (n = 864) into distinct low- and high-risk groups for recurrence (P 50 years (HR: 2.93 (1.44–5.96), P = 0.0002). CAB had an HR of 2.57 (1.26–5.26), P = 0.01) in women with N1 disease. CAB stratified significantly higher proportions (77%) as low-risk over IHC4 (55%) (P < 0.0001). Additionally, 82% of IHC4 intermediate-risk patients were stratified as low-risk by CAB. Accurate risk stratification of European patients by CAB coupled with its similar performance inIndian patients shows that CAB is robust and functions independent of ethnic differences. CAB can potentially prevent overtreatment in a greater number of patients compared to IHC4 demonstrating its usefulness for adjuvant systemic therapy planning in European breast cancer patients

    CLINICOPATHOLOGICAL EVALUATION OF NONMELANOMA SKIN CANCER

    No full text
    Background: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), in combination, are referred to as nonmelanoma skin cancers (NMSCs). NMSC is not as extensively studied in the Asian population as it is in the Caucasian population. Aim: This study sought to evaluate the clinical and histopathologic aspects of NMSC from cases of cutaneous malignancies. Materials and Methods: The present study is a descriptive analysis of NMSC specimens seen at Department of Pathology, SSIMS and RC, Davangere. Histologically diagnosed NMSC, i.e. BCC and SCC specimens from January 2005 to December 2009 were analyzed according to site distribution, risk factors and histological variants. Results: Of the various specimens received during the 5year study period, 60 were histologically categorized as skin malignancies, of which 31(51.6%) cases were of NMSC. SCC was the most common NMSC constituting 26 (83.9%) cases and 5 NMSC cases (16.1%) were of BCC. The most common incidence was among the age group 60-80 years (80%) for BCC and 40-60 years (50%) for SCC. Head and neck was the most common site of presentation with predilection for face. Forty-six percent of SCC was histologically categorized as well differentiated, 42.3% as moderately differentiated and 11.5% as poorly differentiated. Most common histological variant of BCC was solid (nodular) type. Conclusion: NMSC often associated with greater morbidity, necessitating increased efforts to assess risk factors in individuals, to encourage periodic self-examination and professional evaluation of skin and to optimize strategies for earlier diagnosis and treatment

    The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin

    No full text
    Accurate recurrence risk assessment in hormone receptor positive, HER2/neu negative breast cancer is critical to plan precise therapy. CanAssist Breast (CAB) assesses recurrence risk based on tumor biology using artificial intelligence-based approach. We report CAB risk assessment correlating with disease outcomes in multiple clinically high- and low-risk subgroups. In this retrospective cohort of 925 patients [median age-54 (22–86)] CAB had hazard ratio (HR) of 3 (1.83–5.21) and 2.5 (1.45–4.29), P = 0.0009) in univariate and multivariate analysis. CAB's HR in sub-groups with the other determinants of outcome, T2 (HR: 2.79 (1.49–5.25), P = 0.0001); age [16% as high-risk with recurrence rates of up to 12%. In clinically high-risk patients (T2N1 tumors (HR: 2.65 (1.31–5.36), P = 0.003; low-risk DMFS: 92.66 ± 1.88) and in women with luminal-B characteristics (HR: 3.24; (1.69–6.22), P 64% as low-risk. Thus, CAB prognostication was significant in women with clinically low- and high-risk disease. The data imply the use of CAB for providing helpful information to stratify tumors based on biology incorporated with clinical features for Indian patients, which can be extrapolated to regions with similarly characterized patients, South-East Asia
    corecore